2024
Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma
Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma. JHEP Reports 2024, 7: 101294. PMID: 40028344, PMCID: PMC11870164, DOI: 10.1016/j.jhepr.2024.101294.Peer-Reviewed Original ResearchT cell infiltrationHepatocellular carcinomaRadiological-pathological correlationImaging mass cytometryImmune responseT1-weighted MRITumor-infiltrating CD8+ T lymphocytesAnti-tumor immune responseCD8+ T lymphocytesIncreased T lymphocyte infiltrationImaging biomarkersNon-immunogenic tumorsSystemic lymph nodesT lymphocyte infiltrationMurine tumor modelsImmune cell typesLocal tumor therapyPrimary liver cancerNon-invasive imaging biomarkerTesla MRI scannerInduce liver cirrhosisImmunogenic tumorsLocoregional therapySystemic immunotherapyHCC lesionsHuman lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy
Chen J, Nieman L, Spurrell M, Jorgji V, Elmelech L, Richieri P, Xu K, Madhu R, Parikh M, Zamora I, Mehta A, Nabel C, Freeman S, Pirl J, Lu C, Meador C, Barth J, Sakhi M, Tang A, Sarkizova S, Price C, Fernandez N, Emanuel G, He J, Van Raay K, Reeves J, Yizhak K, Hofree M, Shih A, Sade-Feldman M, Boland G, Pelka K, Aryee M, Mino-Kenudson M, Gainor J, Korsunsky I, Hacohen N. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nature Immunology 2024, 25: 644-658. PMID: 38503922, PMCID: PMC12096941, DOI: 10.1038/s41590-024-01792-2.Peer-Reviewed Original ResearchT cellsDendritic cellsImmune hubAssociated with response to immunotherapyMature tertiary lymphoid structuresOrganization of immune cellsIntratumoral immune responsePD-1 blockadeRegulatory dendritic cellsResponse to immunotherapyAbundant T cellsRegulatory T cellsTertiary lymphoid structuresLung cancer specimensHuman lung cancerImmunogenic tumorsImmunotherapy outcomesPD-1Lymphoid structuresCancer specimensImmune cellsLung cancerHuman tumorsImmune responseTumor
2023
The Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal cell carcinomaAdvanced renal cell carcinomaCell carcinomaCentral therapeutic strategyAdvanced renal cancerDurable clinical benefitImmune checkpoint inhibitorsImmunecheckpoint inhibitorsCheckpoint inhibitorsCytokine therapyImmunogenic tumorsMost patientsSystemic therapyClinical benefitCombination therapyCurrent therapiesInterleukin-2Renal cancerTherapeutic strategiesTherapyCarcinomaInhibitorsImmunotherapyPatientsInterferon
2022
Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity
Zhang X, Halberstam A, Zhu W, Leitner B, Thakral D, Bosenberg M, Perry R. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer & Metabolism 2022, 10: 21. PMID: 36457136, PMCID: PMC9714036, DOI: 10.1186/s40170-022-00296-7.Peer-Reviewed Original ResearchTumor microenvironmentAnti-tumor immunityPotential prognostic factorsObesity-associated cancersPotential prognostic predictorPatient RNA-seq dataSubset of studiesImmunogenic tumorsCancer Genome AtlasLymphocyte infiltrationMelanoma cell linesPrognostic factorsPrognostic predictorMetabolic therapyMelanoma subtypesMurine modelImmune functionMetabolic gene expressionMelanoma progressionMelanomaSubstrate metabolismMetabolic flux studiesGene expressionGenome AtlasCell lines
2019
The evolving landscape of immunotherapy in advanced prostate cancer
Patel V, Oh W. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy 2019, 11: 903-912. PMID: 31161846, DOI: 10.2217/imt-2019-0019.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerImmune checkpoint blockadeProstate cancerCheckpoint blockadeAdvent of immune checkpoint blockadeCastration-resistant prostate cancer settingEvolving landscape of immunotherapyImmune resistanceAndrogen synthesis inhibitorsCastration-resistant diseaseCastration-resistant settingLandscape of immunotherapyOvercome immune resistanceImmunosuppressive tumor microenvironmentAdvanced prostate cancerProstate tumor cellsImmunotherapeutic platformImmunogenic tumorsSipuleucel-TTherapeutic vaccinesTumor microenvironmentClinical benefitImmunization modalityTumor cellsLow immunogenicityA phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.
Chesney J, Lutzky J, Thomas S, Nieva J, Munoz Couselo E, Martin-Liberal J, Rodriguez-Moreno J, Cacovean A, Li H, Fardis M, Gettinger S. A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors. Journal Of Clinical Oncology 2019, 37: tps2648-tps2648. DOI: 10.1200/jco.2019.37.15_suppl.tps2648.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsPrior immune checkpoint inhibitorsObjective response rateTIL therapyAdoptive cell therapySystemic therapyCohort 1Cohort 3RECIST 1.1Metastatic melanomaNeck cancerPhase 2 multicenterPrior systemic therapyDurable complete responseOpen-label studyPhase II studyMetastatic melanoma patientsCo-primary endpointsHigh mutational burdenAutologous tumorECOG PSMeasurable diseaseAcceptable toxicityCheckpoint inhibitorsImmunogenic tumorsIntratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses
Jiang X, Fedorova O, Linehan M, Dong H, Pyle A, Iwasaki A. Intratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses. The Journal Of Immunology 2019, 202: 194.28-194.28. DOI: 10.4049/jimmunol.202.supp.194.28.Peer-Reviewed Original ResearchAnti-tumor efficacyRobust anti-tumor immune responseAnti-tumor immune responseTumor microenvironmentNucleic acid-sensing pathwaysT-cell depletionTumor-infiltrating lymphocytesCytosolic nucleic acid-sensing pathwaysB16 melanoma growthVivo anti-tumor efficacyPromising therapeutic agentLong-term survivalRemarkable antitumor effectImmunogenic tumorsInnate cellsCell depletionCancer immunotherapyMouse survivalImmune responseTumor volumeCombination treatmentIntratumoral deliveryAntitumor effectsMelanoma growthTumor subtypes
2018
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples
Givechian KB, Wnuk K, Garner C, Benz S, Garban H, Rabizadeh S, Niazi K, Soon-Shiong P. Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples. Npj Genomic Medicine 2018, 3: 14. PMID: 29928512, PMCID: PMC5998068, DOI: 10.1038/s41525-018-0054-7.Peer-Reviewed Original ResearchFavorable clinical featuresTumor microenvironmentTumor samplesGene signatureClinical featuresT cellsImmune gene expression signatureAntitumor activityT cell abundanceCohort of patientsFavorable clinical outcomeRegulatory T cellsAdaptive immune responsesImmunogenic tumor microenvironmentClusters of patientsPatient tumor samplesM1 macrophage subtypeTreg enrichmentTreg studiesImmunogenic tumorsGene expression signaturesOverall survivalClinical outcomesClinical associationsPatient prognosis
2012
Immunotherapy for metastatic melanoma
Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. Journal Of Cellular Biochemistry 2012, 113: 725-734. PMID: 22006439, DOI: 10.1002/jcb.23402.Peer-Reviewed Original ResearchConceptsMetastatic melanomaPromising investigational approachesTreatment of melanomaImmunogenic tumorsAntitumor immunityCTLA-4Interleukin-2First cytokineInvestigational approachesProlonged responseMelanomaMonoclonal antibodiesImmunotherapyTreatmentIpilimumabPatientsCytokinesTumorsSmall subsetDiseaseImmunityAntibodies
2008
Development of Immunogenic Tumor-Loaded Dendritic Cells Through Physical Perturbation and Apoptotic Cell Loading
Shen X, Berger CL, Tigelaar R, Edelson RL. Development of Immunogenic Tumor-Loaded Dendritic Cells Through Physical Perturbation and Apoptotic Cell Loading. Immunological Investigations 2008, 37: 798-821. PMID: 18991097, DOI: 10.1080/08820130802403358.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationAntigens, CDAntigens, NeoplasmApoptosisB7-1 AntigenCancer VaccinesCD8-Positive T-LymphocytesCell DifferentiationCell Line, TumorCytotoxicity, ImmunologicDendritic CellsHumansImmunoglobulinsLymphocyte ActivationLymphoma, T-CellMechanotransduction, CellularMembrane GlycoproteinsMonocytesPerforinReceptors, CCR7Silicon DioxideConceptsT cellsDendritic cellsAllogeneic T cell proliferationCD8 T cellsLevels of perforinChemokine receptor CCR7T cell proliferationApoptotic tumor cellsUniverse of antigensDC vaccinesImmunogenic tumorsImmature DCsReceptor CCR7TNF-alphaPassage of leukocytesIFN-gammaHuman monocytesMonocytesTumor cellsPotent inductionCell apoptosisPhenotypic conversionCell proliferationApoptotic cellsCells induces
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply